Compare DexCom, Inc. (DXCM) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Total Stock Market Index Fund ETF — how do they compare? DexCom, Inc. trades at $77.89 (market cap $28.06B), while Vanguard Total Stock Market Index Fund ETF trades at $370.7. The key difference: Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | VTI | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | — |
52-Week High | $89.53 | $374.36 |
52-Week Low | $54.84 | $305.74 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
VTI trades at $371.26 with minimal daily movement (+0.03%), maintaining a bullish technical stance supported by moving averages. The ETF's broad exposure to the entire U.S. stock market provides diversification across 3,400+ companies. Recent news highlights strong long-term performance potential, with historical returns averaging nearly 10% annually over 25 years.
The outlook remains positive for long-term investors seeking comprehensive U.S. market exposure at minimal cost (0.03% expense ratio). Key risks include market-wide volatility and economic downturns, though VTI has historically weathered recessions. Analyst sentiment favors VTI for its simplicity and cost-effectiveness in building diversified portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
